Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NASDAQ:DTIL NASDAQ:EQ NASDAQ:IPHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$21.29+0.2%$15.09$3.66▼$42.12$45.25M1.5314,862 shs25,914 shsDTILPrecision BioSciences$8.26+4.3%$7.10$3.53▼$8.82$212.05M1.3303,900 shs167 shsEQEquillium$3.41+10.6%$2.51$0.29▼$3.45$210.43M1.77568,682 shs13,436 shsIPHAInnate Pharma$1.83+1.9%$1.71$1.17▼$2.63$170.00M0.3138,092 shs31,759 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+2.12%-6.96%+48.74%+34.01%+226.27%DTILPrecision BioSciences+8.64%+11.86%+13.63%+44.00%+84.19%EQEquillium+1.95%+7.69%+6.21%+54.00%+893.55%IPHAInnate Pharma+0.56%-0.55%-1.64%+40.63%-2.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$21.29+0.2%$15.09$3.66▼$42.12$45.25M1.5314,862 shs25,914 shsDTILPrecision BioSciences$8.26+4.3%$7.10$3.53▼$8.82$212.05M1.3303,900 shs167 shsEQEquillium$3.41+10.6%$2.51$0.29▼$3.45$210.43M1.77568,682 shs13,436 shsIPHAInnate Pharma$1.83+1.9%$1.71$1.17▼$2.63$170.00M0.3138,092 shs31,759 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+2.12%-6.96%+48.74%+34.01%+226.27%DTILPrecision BioSciences+8.64%+11.86%+13.63%+44.00%+84.19%EQEquillium+1.95%+7.69%+6.21%+54.00%+893.55%IPHAInnate Pharma+0.56%-0.55%-1.64%+40.63%-2.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 1.00SellN/AN/ADTILPrecision BioSciences 2.60Moderate Buy$32.25290.29% UpsideEQEquillium 2.78Moderate Buy$7.57122.36% UpsideIPHAInnate Pharma 2.50Moderate Buy$5.00172.63% UpsideCurrent Analyst Ratings BreakdownLatest APLM, DTIL, EQ, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026EQEquillium Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026DTILPrecision BioSciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.006/4/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.005/28/2026EQEquillium Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.005/28/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/28/2026EQEquillium Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.005/27/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$8.50M5.50N/AN/A($2.89) per share-7.37DTILPrecision BioSciences$34.26M6.22N/AN/A$4.03 per share2.05EQEquillium$41.10M5.24N/AN/A$0.47 per share7.24IPHAInnate Pharma$2.79M61.81N/AN/A($0.26) per share-7.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/AN/ADTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)EQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)IPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)Latest APLM, DTIL, EQ, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A0.960.96DTILPrecision BioSciences0.2914.0214.02EQEquilliumN/A18.6218.62IPHAInnate PharmaN/A1.271.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%DTILPrecision BioSciences37.99%EQEquillium27.05%IPHAInnate Pharma0.16%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/ADTILPrecision BioSciences2.70%EQEquillium17.84%IPHAInnate Pharma31.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics452.20 millionN/ANot OptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataEQEquillium4063.23 million51.95 millionNot OptionableIPHAInnate Pharma22093.92 million63.97 millionNot OptionableAPLM, DTIL, EQ, and IPHA HeadlinesRecent News About These CompaniesInnate Pharma to participate in the Jefferies Global Healthcare ConferenceMay 19, 2026 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comInnate Pharma Reports First Quarter 2026 Business Update and Financial ResultsMay 13, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of April 16, 2026May 12, 2026 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Q1 2026 Business UpdateMay 6, 2026 | businesswire.comInnate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global ConferenceApril 23, 2026 | finanznachrichten.deInnate Pharma to Participate in the D. Boral Capital Global ConferenceApril 23, 2026 | businesswire.comInnate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026April 17, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of April 9, 2026April 13, 2026 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026April 13, 2026 | businesswire.comInnate Pharma SA Sponsored ADRApril 8, 2026 | edition.cnn.comInnate Pharma to Present at the AACR 2026 Oncology Industry Partnering EventApril 8, 2026 | businesswire.comInnate Pharma to Participate in the Kempen Life Sciences ConferenceApril 3, 2026 | businesswire.comInnate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual ReportApril 2, 2026 | businesswire.comInnate Pharma S.A. (IPHA) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comInnate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocusMarch 26, 2026 | fiercebiotech.comFInnate Pharma SA: Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateMarch 26, 2026 | finanznachrichten.deInnate Pharma Reports Full Year 2025 Financial Results and Business UpdateMarch 26, 2026 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial ResultsMarch 19, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of February 19, 2026February 19, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDraining the Tank: Big Oil Runs on FumesBy Jeffrey Neal Johnson | June 17, 20263 ETFs Giving Ready-Made Access to the Discounted International Small-Cap SpaceBy Nathan Reiff | June 14, 2026Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence?By Ryan Hasson | June 2, 2026Robinhood Wants a Bigger Role in IPOs—Here's Why It MattersBy Leo Miller | June 14, 2026Summer Is Coming–But There's No End in Sight for This Crypto WinterBy Jessica Mitacek | June 15, 2026APLM, DTIL, EQ, and IPHA Company DescriptionsApollomics NASDAQ:APLM$21.28 +0.05 (+0.21%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Precision BioSciences NASDAQ:DTIL$8.26 +0.34 (+4.33%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Equillium NASDAQ:EQ$3.40 +0.33 (+10.55%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Innate Pharma NASDAQ:IPHA$1.83 +0.03 (+1.89%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Rezolve AI Stock Has a Short-Squeeze Setup, But Execution Comes First The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
